Total Payments
$86,379
2024 Payments
$1,113
Companies
8
Transactions
51
Medicare Patients
171
Medicare Billing
$29,877
Payment Breakdown by Category
Research$65,133 (75.4%)
Consulting$14,608 (16.9%)
Travel$3,291 (3.8%)
Other$2,600 (3.0%)
Food & Beverage$747.68 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $65,133 | 10 | 75.4% |
| Consulting Fee | $14,608 | 10 | 16.9% |
| Travel and Lodging | $3,291 | 10 | 3.8% |
| Honoraria | $2,500 | 1 | 2.9% |
| Food and Beverage | $747.68 | 18 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $99.72 | 2 | 0.1% |
Payments by Type
Research
$65,133
10 transactions
General
$21,246
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $42,674 | 2 | $0 (2020) |
| Valeant Pharmaceuticals North America LLC | $21,337 | 1 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,763 | 14 | $0 (2024) |
| H. Lundbeck A S | $2,731 | 2 | $0 (2018) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,972 | 11 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $1,585 | 10 | $0 (2019) |
| Janssen Research & Development, LLC | $1,214 | 8 | $0 (2017) |
| ITI, Inc. | $103.10 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,113 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($1,113) |
| 2023 | $8,301 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,275) |
| 2022 | $5,521 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,375) |
| 2021 | $30.98 | 1 | ITI, Inc. ($30.98) |
| 2020 | $11,418 | 3 | Bausch Health US, LLC ($10,668) |
| 2019 | $1,547 | 8 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,122) |
| 2018 | $34,736 | 3 | Bausch Health US, LLC ($32,005) |
| 2017 | $23,711 | 18 | Valeant Pharmaceuticals North America LLC ($21,337) |
All Payment Transactions
51 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $890.00 | General |
| 01/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $222.50 | General |
| 09/07/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: PSYCHIATRY | ||||||
| 05/24/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,785.00 | General |
| 05/24/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 05/24/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 05/13/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $44.14 | General |
| 04/25/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,335.00 | General |
| 03/13/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $623.98 | General |
| 03/13/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $312.17 | General |
| 10/12/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,905.00 | General |
| 10/12/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 10/12/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 09/19/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $46.12 | General |
| Category: PSYCHIATRY | ||||||
| 09/15/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $49.86 | General |
| Category: PSYCHIATRY | ||||||
| 09/15/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $49.86 | General |
| Category: PSYCHIATRY | ||||||
| 09/07/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 08/30/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,245.00 | General |
| 10/29/2021 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $30.98 | General |
| Category: PSYCHIATRY | ||||||
| 04/08/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: PSYCHIATRY | ||||||
| 01/27/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: PSYCHIATRY | ||||||
| 01/02/2020 | Bausch Health US, LLC | TASMAR (Drug) | — | Cash or cash equivalent | $10,668.47 | Research |
| Study: 2016-2007 Grant • Category: NEUROLOGY | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | Cash or cash equivalent | $378.60 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/06/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $186.19 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
| 12/05/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $126.79 | Research |
| Study: A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER • Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 2016-2007 Grant | Bausch Health US, LLC | $42,674 | 2 |
| 2016-2007 Grant | Valeant Pharmaceuticals North America LLC | $21,337 | 1 |
| A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $691.58 | 3 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $430.46 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 52 | 126 | $23,943 | $9,829 |
| 2022 | 1 | 25 | 71 | $12,782 | $5,658 |
| 2021 | 3 | 53 | 106 | $17,004 | $7,977 |
| 2020 | 2 | 41 | 102 | $17,714 | $6,413 |
Total Patients
171
Total Services
405
Medicare Billing
$29,877
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 29 | 95 | $17,830 | $7,440 | 41.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 11 | 11 | $3,813 | $1,261 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 20 | $2,300 | $1,128 | 49.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 25 | 71 | $12,782 | $5,658 | 44.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 17 | 38 | $7,628 | $3,107 | 40.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 17 | 32 | $5,573 | $2,773 | 49.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 36 | $3,803 | $2,097 | 55.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 30 | 79 | $13,192 | $4,818 | 36.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 23 | $4,522 | $1,595 | 35.3% |
About Jon Grant
Jon Grant is a Psychiatry healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235163759.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jon Grant has received a total of $86,379 in payments from pharmaceutical and medical device companies, with $1,113 received in 2024. These payments were reported across 51 transactions from 8 companies. The most common payment nature is "" ($65,133).
As a Medicare-enrolled provider, Grant has provided services to 171 Medicare beneficiaries, totaling 405 services with total Medicare billing of $29,877. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Chicago, IL
- Active Since 07/10/2006
- Last Updated 10/24/2022
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1235163759
Products in Payments
- TASMAR (Drug) $64,011
- ESCITALOPRAM (Drug) $2,731
- REXULTI (Drug) $1,541
- CAPLYTA (Drug) $103.10
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Chicago
Dr. Michelle Dees, Md, MD
Psychiatry — Payments: $523,545
Psychiatry $523,545
Mitchell Glaser, Md, MD
Psychiatry — Payments: $494,195
Psychiatry $494,195
Peter Weiden, Md, MD
Psychiatry — Payments: $202,917
Psychiatry $202,917
Emil Coccaro, M.d, M.D
Psychiatry — Payments: $104,905
Psychiatry $104,905
Dr. Richard Baer, M.d, M.D
Psychiatry — Payments: $84,125
Psychiatry $84,125
K Ranga Krishnan, M.d, M.D
Psychiatry — Payments: $71,680
Psychiatry $71,680